tumor mutational burden Apr 6, 2022 BostonGene Closes $150M Series B Funding Round Mar 15, 2022 Illumina Obtains CE-IVD Marking for European Version of TSO Comprehensive Assay Mar 10, 2022 Oxford BioDynamics Gathering Real-World Data on Checkpoint Inhibitor Response Predictor Premium Jan 7, 2022 Precision Oncology in 2021: Growing Complexity, Refining Liquid Biopsy Use, Focus on Access Gaps Dec 30, 2021 Top 10 Precision Oncology Articles in 2021: Liquid Biopsy, Difficult Reimbursement, TMB Debates Dec 20, 2021 Survey of Precision Oncology Programs Shows Rapid Pace of Advances a Major Challenge for Oncologists Oct 8, 2021 TGen Study Highlights Value of Repeat Tumor Profiling for Pediatric Solid Tumors Premium Aug 19, 2021 Mounting Research Backs MHC as Immune Checkpoint Inhibitor Biomarker Premium Jul 29, 2021 Genomes of Advanced Neuroendocrine Neoplasms Unveil Subtypes, Treatment Clues Jul 9, 2021 Strata Oncology Developing Integrated TMB, PD-L1, PD-L2 Test to Predict Checkpoint Inhibitor Benefit Premium Apr 29, 2021 TMB-High Status Does Not Predict Opdivo-Yervoy Response in Pan-Tumor Analysis Apr 14, 2021 Tecentriq Response Analysis in MyPathway Study Bolsters Case for Higher TMB Cutoff Premium Apr 1, 2021 Tumor-Only Sequencing for TMB Measurements May Inflate Scores in Black Patients Premium Mar 25, 2021 Oncologists Look to FDA as New Publications Poke Holes in TMB-High Keytruda Approval Premium Feb 18, 2021 MSK Study Underscores Need to Validate Cancer-Specific Tumor Mutational Burden Cutoffs Premium Jan 7, 2021 MSK Researchers Chip Away at TMB Unknowns, Clarify Role in Predicting Immunotherapy Benefit Premium Jan 5, 2021 Precision Oncology in 2020: Pandemic Lessons, Biomarker Controversies, Community Access Gaps Premium Dec 29, 2020 Top 20 Precision Oncology Articles in 2020: Pandemic, FDA Approvals, TMB, Liquid Biopsy CDx, More Nov 17, 2020 Diagnostics Firms, Lab Providers Form Genomic Profiling Coalition Nov 9, 2020 FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Lynparza Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
